Recently approved beta-emitting 177Lu-DOTATATE (Lutathera®, 2018) targeting somatostatin-2 receptors in patients with metastatic neuroendocrine tumors and 177Lu-PSMA-617 (Pluvicto®, 2022) targeting prostate-specific membrane antigen (PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC) will clearly shift targeted radionuclide therapy (TRT) into the mainstream of cancer treatment. The gene discussed is FOLH1; the disease is cancer.